Although there was an increase in the incidence of AAA with the elevated dosage of MRS2578 over 4 weeks of treatment of Ang II, the difference in the AAA incidence among the three Ang II perfusion groups did not reach statistical significance (p = 0.746; Figure 1(a)). The gene discussed is AGT; the disease is triple-A syndrome.